首页> 美国卫生研究院文献>Vascular Health and Risk Management >Short-term effect of the HMG-CoA reductase inhibitor rosuvastatin on erythrocyte nitric oxide synthase activity
【2h】

Short-term effect of the HMG-CoA reductase inhibitor rosuvastatin on erythrocyte nitric oxide synthase activity

机译:HMG-CoA还原酶抑制剂瑞舒伐他汀对红细胞一氧化氮合酶活性的短期影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Prevention and treatment of cardiovascular disorders by HMG-CoA reductase inhibitors (or statins), beyond their lipid-lowering properties, have been demonstrated including activation of the endothelial nitric oxide synthase (eNOS). Beside endothelial cells, red blood cells (RBCs) possess NOS and produce nitric oxide (NO), which contributes to RBC deformability. The present study tested the capacity of statins to activate NOS in RBCs and subsequently to modulate RBC deformability in vitro. Blood samples of healthy young volunteers were incubated with or without rosuvastatin. Afterwards RBC-NOS activity and RBC deformability were determined. Rosuvastatin incubation significantly increased NOS phosphorylation, NOS dependent NO-formation, and RBC deformability. The NOS inhibitor NG- monomethyl-L-arginine reversed the stimulatory effect of rosuvastatin on RBC-NOS activity. This NO dependent effect of rosuvastatin might have an important influence on microcirculation and may offer new perspectives for the therapeutic use of statins.
机译:已经证明,通过HMG-CoA还原酶抑制剂(或他汀类药物)可预防和治疗心血管疾病,除了具有降低脂质的特性外,还包括激活内皮一氧化氮合酶(eNOS)。除内皮细胞外,红细胞(RBC)具有NOS并产生一氧化氮(NO),这有助于RBC变形。本研究测试了他汀类药物激活红细胞中NOS并随后在体外调节RBC变形能力的能力。将健康的年轻志愿者的血液样本与或不与瑞舒伐他汀一起孵育。然后测定RBC-NOS活性和RBC可变形性。瑞舒伐他汀孵育显着增加了NOS磷酸化,NOS依赖性NO的形成和RBC的可变形性。 NOS抑制剂NG-单甲基-L-精氨酸逆转了瑞舒伐他汀对RBC-NOS活性的刺激作用。瑞舒伐他汀的这种NO依赖性效应可能对微循环产生重要影响,并可能为他汀类药物的治疗用途提供新的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号